The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (5 analysts) rates it none, with a mean price target of $23. Insiders have been net buyers over the past quarter.
Saratoga Investment Corp
SAR · the NYSE · USD · Market cap $365M
Saratoga Investment Corp.
FAIL · Does not pass the screenPrice as of 14 Oct 2026Daily close, not a live quoteLast reviewed 14 days ago
Screened 2026-10-14 · the tape above runs as of 10:12 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price14.92 USD at the 14 Oct 2026 close
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 2.39)
- Last reviewed14 Oct 2026 (14 days ago)
A summary of the dated readings below, not a live quote and not advice.
What this means: price 14.92 against the desk's fair-value range, base estimate 20.98, over the last year.
- Trend Distribution
- Insiders insiders bought, latest filing 2026-10-08
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 2.39, read 2026-10-25
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
Saratoga Investment Corp holds its Distribution at $14.92. Consolidating, no directional conviction, held for 8 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 8 days |
| Price at the screen | $14.92 |
| Valuation | 7.64 trailing · 8.38 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 0.59 |
Five Screens, Shown in Full
Does not pass. Excluded industry: Asset Management
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Excluded industry: Asset Management | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Saratoga Investment does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when SAR's ethical verdict changes
Today SAR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value range in USD, drawn from the 2026-10-14 screen. The gold marker is the market price at the same screen. A 40.6% margin of safety to the base estimate.
Third-party analyst targets: 5 covering, consensus None. The average target sits +54% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-14 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | 8.4xvery cheap relative to earnings |
| Trailing P/E | 7.6xvery cheap relative to earnings |
| EPS, trailing | 2.31 |
| EPS, forward | 2.11 |
| Revenue growth | -0.6%revenue is shrinking |
| Profit margin | 29.1%healthy profit margins |
| Return on equity | 9.3%a modest return on shareholder capital |
| Dividend yield | 1,337.00% |
| Debt to equity | 1.83a meaningful debt load worth watching |
| Beta | 0.59steadier than the market |
| 52-week range | 20.78 - 25.64 |
| Moat | NONE |
| Market cap | $365M |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeSAR trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 15.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (5 analysts) rates it none, with a mean price target of $23. Insiders have been net buyers over the past quarter.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 21.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (5 analysts) rates it none, with a mean price target of $23. Since the last review it its composite score rose.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (5 analysts) rates it none, with a mean price target of $23.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (5 analysts) rates it none, with a mean price target of $23.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 7%. Our forward projection puts the odds of a 10% gain over the next month near 13%. The street (5 analysts) rates it none, with a mean price target of $23.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-08 | Oberbeck Christian L | CEO, Dir | P - Purchase | 30,000 | $445,800 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-09-11 | Diana Harshbarger | Republican | buy | 15K–50K |
| 2026-07-15 | Lisa McClain | Republican | buy | 50K–100K |
| 2026-07-15 | Lisa McClain | Republican | buy | 50K–100K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $21.59 | +3.5% | $0.25 | $1,047 | +4.7% |
| 2 months | $21.81 | +2.5% | $0.50 | $1,048 | +4.8% |
| 3 months | $21.71 | +2.9% | $0.75 | $1,064 | +6.4% |
| 6 months | $21.53 | +3.8% | $1.50 | $1,108 | +10.8% |
| 1 year | $20.98 | +6.5% | $3.25 | $1,220 | +22.0% |
| 2 years | $17.92 | +24.7% | $7.31 | $1,655 | +65.5% |
| 3 years | $18.47 | +21.0% | $10.17 | $1,761 | +76.1% |
| 5 years | $14.74 | +51.7% | $14.63 | $2,510 | +151.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SAR does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.